4.2-classify | Manufacturers classify each device and IVD by the harmonized risk-based rules, applying the higher class where two could apply, and accept that the NRA may review or overturn the c | 0 |
4.3-EP | Show that every device conforms to the applicable essential principles of safety and performance throughout its life cycle, preferably by applying recognised international standard | 0 |
4.3-changes | Keep changes to intended purpose, design, specifications, labelling or manufacture in conformity with the essential principles, classify changes as substantial or not under a proce | 0 |
4.3.1-clinical | Compile clinical evidence and a documented clinical evaluation under the QMS as part of the technical documentation, with new data for novel high-risk devices and investigations to | 0 |
4.4.3-IVD | For IVDs, establish clinical evidence covering scientific validity, analytical performance and clinical performance, with performance studies on human specimens to ISO 20916 | 0 |
4.4.4-lot | Support NRA-required lot verification testing of high-risk (Class D) IVDs and control transport and storage so lot performance is not affected | 0 |
5.1-law | Government: give device regulation a sound legal basis that defines products and regulated parties, requires only safe, performing, quality devices on the market, empowers and hold | 0 |
5.2-5.4-plan | Government and NRA: carry out a gap analysis with stakeholders, publish a risk-based implementation plan aligned with resources, and monitor implementation with indicators (such as | 0 |
5.5-5.7-NRA | Government: appoint an NRA with independent decision-making, defined governance and public performance reporting, adequate and transparent funding (fair, reviewed user fees if any) | 0 |
5.8-9.3-capacity | NRA: build and maintain regulatory competence through recruitment, retention, formal selection and annual training plans, evidence of staff competence, expert committees and extern | 0 |
5.9-reliance | Government and NRA: provide in law for reliance on and recognition of reference regulators, CABs and WHO, keep national-only functions in-country, and join information-sharing netw | 0 |
6.1-stepwise | NRA: implement controls stepwise, enforcing the basic-level controls before adopting expanded-level ones, and only when the legal basis and resources exist | 0 |
6.2.1.1-6.2.1.2-NRA | NRA: adopt a harmonized risk classification scheme with guidance and a voluntary classification consultation, require declarations of conformity with the essential principles, and | 0 |
6.2.2.2-DoC | Draw up, hold and supply on request a signed declaration of conformity for each device with the minimum content, and keep the supporting technical documentation available for verif | 0 |
6.2.2.3-QMS | Establish and maintain, for every device class, a QMS with records suited to the processes and products, aligned with ISO 13485 and ISO 14971 at their latest editions | 0 |
6.2.2.4-labelling | Provide labels and instructions suited to the intended user and in an accepted language, with intended purpose, contraindications, warnings, identification for traceability, UDI wh | 0 |
6.2.2.5-advertising | Advertise and promote devices only within their authorized intended purpose, with evidence-backed claims, to appropriate audiences, and never falsely, misleadingly or deceptively | 0 |
6.2.2.6-exceptions | Government and NRA: define exemptions and enforcement discretion for emergencies, humanitarian use, individual patients, clinical investigations, exhibitions and donations, with ri | 0 |
6.2.3-AR | A manufacturer outside the jurisdiction appoints a local authorized representative, under an agreement setting out who meets each national requirement and keeps distribution record | 0 |
6.2.3-NRA-registers | NRA: run establishment registration and device listing systems, check them periodically, publish them, and specify listing data and nomenclature | 0 |
6.2.3.1-registration | Register each local manufacturer, authorized representative, importer and distributor establishment with the NRA, with a separate registration for each role, and notify significant | 0 |
6.2.3.1.1-AR-duties | As authorized representative, give the NRA business and contact details, list devices and keep the list current, support authorization applications, relay feedback and FSCA, cooper | 0 |
6.2.3.1.2-importer | Importers and distributors register, supply only conforming devices with proper labelling and instructions, pass feedback and complaints to the manufacturer or representative, keep | 0 |
6.2.3.2-listing | Submit and keep current a listing of each device placed on the national market, using an internationally recognised nomenclature and information consistent with the technical docum | 0 |
6.2.3.3-NRA-import | NRA: decide which device categories need extra import controls, train customs, designate ports of entry, and hold powers to stop non-compliant imports | 0 |
6.2.3.3-import | Supply the import documentation the NRA requires (QMS certificates, proof of authorization in the exporting country, declaration of conformity, test reports), import through design | 0 |
6.2.4-NRA-vigilance | NRA: run a reporting system for adverse events from manufacturers, users and patients, forward reports for investigation, assess risks, exchange information with other NRAs, issue | 0 |
6.2.4.1-AE | Report to the NRA serious public health threats, deaths or serious deteriorations in health, and failures or design, labelling or use problems that could cause them, plus any false | 0 |
6.2.4.2-FSCA | Notify the NRA promptly of every field safety corrective action undertaken in the country, issue field safety notices, and allow the NRA to monitor the effectiveness of corrective | 0 |
6.2.4.3-NRA-enforce | NRA: enforce against non-compliant, unsafe or falsified devices with proportionate measures, consult manufacturers before public alerts, inform the public and share concerns with t | 0 |
6.2.4.3-withdrawal | Cooperate with NRA enforcement against unsafe or non-compliant devices, including withdrawal, quarantine and disposal, and review technical documentation and revise labelling when | 0 |
6.2.4.5-6.3.3.2-MS | NRA: conduct risk-based market surveillance using distribution-chain risk, user feedback and manufacturer surveillance data, with focused sampling and testing through collaborating | 0 |
6.3.1-NRA-premarket | NRA: oversee clinical investigations, recognise and supervise CABs, adopt a nomenclature system and a UDI system aligned with international practice, and control advertising | 0 |
6.3.1.1-CI | Sponsors obtain prior NRA authorization for new clinical investigations, run them under ethics committee oversight with informed consent to ISO 14155, and report progress and serio | 0 |
6.3.1.5-UDI | Where the NRA adopts UDI, assign UDI-DIs and UDI-PIs through an accredited issuing agency, apply them to labels and packaging in human- and machine-readable form, and submit UDI-DI | 0 |
6.3.2-NRA-review | NRA: verify manufacturers' QMS by audit or reliance on valid certificates, review submissions against transparent criteria using harmonized formats, apply extended review triggers, | 0 |
6.3.3.1-PMS | Operate post-market surveillance within the QMS that collects user feedback, reviews the benefit-risk profile, reports the required events, evaluates and takes corrective action, w | 0 |
6.3.3.3-NRA-inspect | NRA: inspect registered establishments on a risk basis (scheduled or unannounced), rely on trusted inspections where possible, and license, suspend or withdraw registrations for un | 0 |
6.3.3.3.1-distribution | Manufacturers select and contract qualified distributors and specify storage, handling, transport, installation, servicing, traceability and disposal requirements; distributors run | 0 |
6.3.3.4-local | Government and NRA: support quality local production with good regulatory practice, apply the same controls to local and imported devices, offer pre-submission meetings and imparti | 0 |
6.3.3.5-testing | NRA: avoid routine testing, use accredited laboratories (ISO/IEC 17025, ISO 15189) under defined agreements or reliance for targeted testing of falsified, incident-related, priorit | 0 |
7.3-7.6-NRA-pathways | NRA: establish emergency use authorization criteria and validity limits, borderline product and combination product designation processes with published decisions and appeal, and a | 0 |
7.3-EUA | Applicants for emergency use authorization submit the evidence available, keep seeking and submitting new evidence, monitor post-market safety and performance, and move to full ass | 0 |
7.5-combination | For medicine-device combination products, follow the designated regulatory pathway (by primary mode of action), meet the GMP or QMS, verification and post-market requirements set f | 0 |
7.6-donations | Donors ensure donated devices meet the receiving country's requirements, respond to an expressed clinical need, are complete, documented in a local language, suited to local condit | 0 |
8.1-disposal | Give users decontamination and disposal instructions, and dispose of devices at end of life (or earlier if hazardous) safely in line with manufacturer recommendations and local rul | 0 |
8.2-8.4-NRA-policy | NRA: set policy on reprocessing single-use devices and refurbishing, and build oversight of SaMD and machine learning devices, including local dataset representativeness, update an | 0 |
8.2-reprocessing | Do not reuse single-use devices except under NRA-permitted conditions; an entity reprocessing them becomes the manufacturer, with risk assessment, validated reprocessing, a QMS, tr | 0 |
8.3-refurbishing | Refurbishers meet the same requirements as original manufacturers (QMS certificate, technical documentation, declaration of conformity) and identify refurbished devices as such on | 0 |
8.4-SaMD | For SaMD and software in devices, including machine learning devices, demonstrate scientific validity, analytical validity and clinical performance, run life-cycle processes under | 0 |
8.5-SF | Report suspected substandard or falsified devices to the NRA, buy and distribute only through reliable sources, and use UDI and track-and-trace tools to protect supply chain integr | 0 |
8.6-CDx | For companion diagnostics, obtain authorization for clinical performance studies and market entry, label the corresponding medicine where the test is tied to it, and report test fa | 0 |
8.7-8.9-WHO | WHO prequalification, the collaborative registration procedure and emergency use listing | 0 |
9.1-stakeholders | Government and NRA: involve stakeholders throughout the regulatory process and assess the public health, economic and social impact of proposed controls | 0 |
purpose | Purpose, audience and structure of the GMRF | 0 |
terms-definitions | Terminology and the harmonized definitions of medical device and IVD | 0 |